News | June 20, 2014

MRI Brain Scans Detect People With Early Parkinson's

Oxford University Research Brain MRI Resting-state fMRI Parkinson's

June 20, 2014 — Oxford University researchers funded by Parkinson's UK have developed a simple and quick magnetic resonance imaging (MRI) technique that offers promise for early diagnosis of Parkinson's disease.

The team demonstrated that its new MRI approach can detect people who have early-stage Parkinson's disease with 85 percent accuracy, according to research published in Neurology, the medical journal of the American Academy of Neurology.

“At the moment we have no way to predict who is at risk of Parkinson's disease in the vast majority of cases,” says Dr. Clare Mackay of the Department of Psychiatry at Oxford University, one of the joint lead researchers. “We are excited that this MRI technique might prove to be a good marker for the earliest signs of Parkinson's. The results are very promising.”

Claire Bale, research communications manager at Parkinson's UK, explains: “This new research takes us one step closer to diagnosing Parkinson's at a much earlier stage — one of the biggest challenges facing research into the condition. By using a new, simple scanning technique the team at Oxford University have been able to study levels of activity in the brain, which may suggest that Parkinson's is present. One person every hour is diagnosed with Parkinson's in the UK, and we hope that the researchers are able to continue to refine their test so that it can one day be part of clinical practice.'

The researchers from the Oxford Parkinson's Disease Centre also received support from the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre and the NIHR Clinical Research Network: Dementias and neurodegeneration (DeNDRoN).

Parkinson's disease is characterized by tremor, slow movement, and stiff and inflexible muscles. It's thought to affect around 1 in 500 people, meaning there are an estimated 127,000 people in the United Kingdom with the condition. There is currently no cure for the disease, although there are treatments that can reduce symptoms and maintain quality of life for as long as possible.

Parkinson's disease is caused by the progressive loss of a particular set of nerve cells in the brain, but this damage to nerve cells will have been going on for a long time before symptoms become apparent.

If treatments are to be developed that can slow or halt the progression of the disease before it affects people significantly, the researchers say, we need methods to be able to identify people at risk before symptoms take hold.

Conventional MRI cannot detect early signs of Parkinson's, so the Oxford researchers used an MRI technique, called resting-state fMRI, in which people are simply required to stay still in the scanner. They used the MRI data to look at the 'connectivity,' or strength of brain networks, in the basal ganglia — part of the brain known to be involved in Parkinson's disease.

The team compared 19 people with early-stage Parkinson's disease while not on medication to 19 healthy people, matched for age and gender. They found that the Parkinson's patients had much lower connectivity in the basal ganglia.

The researchers were able to define a cut-off or threshold level of connectivity. Falling below this level was able to predict who had Parkinson's disease with 100 percent sensitivity (it picked up everyone with Parkinson's) and 89.5 percent specificity (it picked up few people without Parkinson's — there were few false positives).

Mackay explains: “Our MRI approach showed a very strong difference in connectivity between those who had Parkinson's disease and those that did not. So much so, that we wondered if it was too good to be true and carried out a validation test in a second group of patients. We got a similar result the second time.”

The scientists applied their MRI test to a second group of 13 early-stage Parkinson's patients as a validation of the approach. They correctly identified 11 out of the 13 patients (85 percent accuracy).

“We think that our MRI test will be relevant for diagnosis of Parkinson's,” says joint lead researcher Dr. Michele Hu of the Nuffield Department of Clinical Neurosciences at Oxford University and the Oxford University Hospitals NHS Trust. “We tested it in people with early-stage Parkinson's. But because it is so sensitive in these patients, we hope it will be able to predict who is at risk of disease before any symptoms have developed. However, this is something that we still have to show in further research.”

To see if this is the case, the Oxford University researchers are now carrying out further studies of their MRI technique with people who are at increased risk of Parkinson's.

For further information: www.ox.ac.uk

Related Content

Houston Methodist Hospital Enters Multi-Year Technology and Research Agreement With Siemens Healthineers
News | Imaging | August 17, 2017
Houston Methodist Hospital and Siemens Healthineers have entered into a multi-year agreement to bring cutting-edge...
Carestream Launches MR Brain Perfusion and Diffusion Modules for Vue PACS
Technology | Advanced Visualization | August 16, 2017
Carestream Health recently introduced new MR (magnetic resonance) Brain Perfusion and MR Brain Diffusion modules that...
ISMRM Issues Guidelines for MRI Gadolinium Contrast Agents
News | Contrast Media | August 15, 2017
The International Society for Magnetic Resonance in Medicine (ISMRM) has provided new guidance in the use of contrast...
MRI Reveals Striking Brain Differences in People with Genetic Autism

Example images for a control participant , a deletion carrier, and a duplication carrier. In the sagittal image of the deletion carrier, the thick corpus callosum, dens and craniocervical abnormality, and cerebellar ectopia are shown. For the duplication carrier, the sagittal image shows the thin corpus callosum and the axial image shows the increased ventricle size and decreased white matter volume. Image courtesy of the Radiological Society of North America (RSNA).

News | Neuro Imaging | August 09, 2017
August 9, 2017 — In the first major study of its kind, researchers using magnetic...
GE Healthcare's Signa Premier MRI Receives FDA 510(k) Clearance
Technology | Magnetic Resonance Imaging (MRI) | August 04, 2017
GE Healthcare announced Signa Premier, a new wide bore 3.0T magnetic resonance imaging (MRI) system, is now available...
Clinical Data Supports Use of Xoft System for Endometrial Cancer
News | Brachytherapy Systems | August 03, 2017
Researchers presented clinical data supporting use of the Xoft Axxent Electronic Brachytherapy (eBx) System for the...
brain with chronic traumatic injury
News | Magnetic Resonance Imaging (MRI) | August 02, 2017
Fighters are exposed to repeated mild traumatic brain injury (mTBI), which has been associated with neurodegenerative...
News | Image Guided Radiation Therapy (IGRT) | July 31, 2017
Elekta’s magnetic resonance radiation therapy (MR/RT) system will be the subject of 21 abstracts at the 59th American...
Overlay Init